1 Valiron O, Caudron N, Job D. Microtubule dynamics. Cell Mol Life Sci, 2001, 58: 2069-2084？？
[2]
2 Dumontet C, Jordan M A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov, 2010, 9: 790-803？？
[3]
3 Zhou J, Giannakakou P. Targeting microtubule for cancer chemotherapy. Curr Med Chem Anti cancer Agents, 2005, 5: 65-71？？
[4]
4 Siemann D W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vasculardisrupting agents. Cancer Treat Rev, 2011, 37: 63-74？？
[5]
5 Mohan R, Banerjee M, Ray A, et al. Antimitotic sulfonamides inhibit microtubule assembly dynamics and cancer cell proliferation.Biochemistry, 2006, 45: 5440-5449？？
7 Hsieh H P, Liou J P, Mahindroo N. Pharmaceutical design of antimitotic agents based on combretastatins. Curr Pharm Des, 2005, 11:1655-1677？？
[8]
8 Nguyen T L, Mcgrath C, Hermone A R, et al. A common pharmacophore for a diverse set of colchicine site inhibitors using astructure-based approach. J Med Chem, 2005, 48: 6107-6116？？
10 Chiang Y K, Kuo C C, Wu Y S, et al. Generation of ligand-based pharmacophore model and virtue screening for identification of newtubulin inhibitors with potent anticancer activity. J Med Chem, 2009, 52: 4221-4233？？
[11]
11 Wolber G, Langer T. LigandScout: 3-D Pharmacophores derived from protein-bound ligands and their use as virtual screening filters. JChem Inf Model, 2005, 45: 160-169？？
[12]
12 Carmichael J, Defgraf W G, Gazdar A F, et al. Evaluation of a tetrazolium-based semiautomated colorimetrie assay: assessment ofchemosensitivity testing. Cancer Res, 1987, 47: 936-942
[13]
13 Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst, 1990, 82:1107-1112？？
[14]
14 Ravelli R B, Gigant B, Curmi P A, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature,2004, 428: 198-202？？
[15]
15 Dorleans A, Gigant B, Ravelli R B, et al. Variations in the colchicine-binding domain provide insight into the structural switch of tubulin.Proc Natl Acad Sci USA, 2009, 106: 13775-13779？？
[16]
16 Hastie S B, Macdonald T L. Binding of colchicine to tubulin mechanisms of ligand association with tubulin. Biochem Pharmacol, 1990, 39:1271-1276？？
[17]
17 Stareta M E, Hastie S B. Synthesis and tubulin binding of novel C-10 analogues of colchicine. J Med Chem, 1993, 36: 758-764？？
[18]
18 Banwell M G, Hamel E, Hockless D C, et al. 4, 5-Diaryl-1H-pyrrole-2-carboxylates as combretastatin A-4/lamellarin T hybrids: synthesisand evaluation as anti-mitotic and cytotoxic agents. Bioorg Med Chem, 2006, 14: 4627-4638
[19]
19 Liou J P, Wu Z Y, Kuo C C, et al. Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors. J MedChem, 2008, 51: 4351-4355
[20]
21 Nogales E, Wolf S, Downing K H. Structure of the alphabeta tubulin dimer by electron crystallography. Nature, 1998, 391: 199-203？？
[21]
22 Gaukroger K, Hadfield J A, Lawrence N J, et al. Structural requirements for the interaction of combretastatins with tubulin: how importantis the trimethoxy unit? Org Biomol Chem, 2003, 1: 3033-3037
[22]
23 Ducki S, Mackenzie G, Lawerence N J, et al. Quantitative structure-sctivity relationship (5D-QSAR) study of combretastatin-like analoguesas inhibitors of tubulin assembly. J Med Chem, 2005, 48: 457-465？？
[23]
20 Romagnoli R, Baraldi P G, Cruz-Lopez O, et al. Synthesis of novel antimitotic agents based on 2-amino-3-aroyl-5-(hetero)arylethynylthiophene derivatives. Bioorg Med Chem Lett, 2011, 21: 2746-2751？？
